BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

†BRILIQUE (ticagrelor) 90mg twice daily  in combination with  acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

Product Information

Other adverse events1

For a full list of adverse events, please consult the BRILIQUE (ticagrelor) Summary of Product Characteristics, available at http/www.medicines.org.uk.

The most commonly reported adverse reactions in patients treated with BRILIQUE (ticagrelor) are bleeding and dyspnoea.

Very common

The following adverse reactions are very common (≥1/10) with BRILIQUE (ticagrelor):

  • Blood disorder bleedinga
  • Hyperuricaemiab
  • Dyspnoea

Common

The following adverse reactions are common (≥1/100 to <1/10) with BRILIQUE (ticagrelor):

  • Gout/gouty arthritis
  • Dizziness, syncope and headache
  • Vertigo
  • Hypotension
  • Respiratory system bleedingsc
  • Gastrointestinal haemorrhage,d diarrhoea, nausea, dyspepsia, constipation
  • Subcutaneous or dermal bleeding,e rash, pruritus
  • Urinary tract bleedingf
  • Blood creatinine increaseb
  • Post-procedural haemorrhage, traumatic bleedingsg

ae.g. an increased tendency to bruise, spontaneous haematoma, haemorrhagic diathesis

be.g. frequencies derived from lab observations (uric acid increases to >upper limit of normal from baseline below or within reference range. Creatinine increases of >50% from baseline) and not crude adverse event report frequency

ce.g. epistaxis, haemoptysis

de.g. gingival bleeding, rectal haemorrhage, gastric ulcer haemorrhage

ee.g. ecchymosis, skin haemorrhage, petechiae

fe.g. haematuria, cystitis haemorrhagic

ge.g. contusion, traumatic haematoma, traumatic haemorrhage

Back to top